SIU Academy® - Official eLearning Portal of SIU (Société Internationale d'Urologie)

SIU Academy®. Faculty / Presenters . 11/07/20; 312685 Topic: Treatment
 Faculty / Presenters
Faculty / Presenters
About this activity
Over the past 10 years, advancements in genomics and sequencing technologies have paved the way to a more in-depth understanding of the pathogenesis of bladder cancer, leading to the discovery of new targets. The development of several novel therapies such as checkpoint inhibitors, and other targeted therapies have allowed for a more optimized treatment approach. A number of new drugs in 2019 and early 2020 were approved by the U.S. Food and Drug Administration (FDA) for all stages of bladder cancer.


Wes Kassouf, MD, CM, FRCSC
Stephen Jarislowsky Chair in Urology
Professor and Vice Chair, Dept of Surgery
McGill University

Arjun Balar, MD
Associate Professor of Medicine
Director – Genitourinary Medical Oncology Program
Medical Director – Clinical Trials Office
Perlmutter Cancer Center
United States

Kilian M Gust, MD
Department of Urology
Medical University of Vienna

Kala S. Sridhar MD, MSc, FRCPC
Medical Oncologist, Princess Margaret Hospital
Associate Professor, University of Toronto
Chair, GU Medical Oncologists of Canada

This educational activity is supported by SIU Corporate Sponsor Bristol Myers Squibb.


By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies